Genenta Science (GNTA) Expected to Announce Earnings on Friday

Genenta Science (NASDAQ:GNTA) is anticipated to release its results before the market opens on Friday, March 27th. Analysts expect Genenta Science to post earnings of ($0.3641) per share for the quarter.

Genenta Science Price Performance

NASDAQ:GNTA opened at $0.63 on Friday. Genenta Science has a 1-year low of $0.61 and a 1-year high of $10.00. The firm has a fifty day simple moving average of $1.03 and a 200 day simple moving average of $1.98.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genenta Science in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Genenta Science

A number of hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new position in shares of Genenta Science during the 3rd quarter worth approximately $41,000. SmartHarvest Portfolios LLC bought a new stake in Genenta Science in the 4th quarter valued at $26,000. Alyeska Investment Group L.P. acquired a new stake in Genenta Science during the 4th quarter valued at $328,000. Norges Bank bought a new position in Genenta Science during the fourth quarter worth $337,000. Finally, Weiss Asset Management LP bought a new position in Genenta Science during the fourth quarter worth $480,000. 15.13% of the stock is owned by institutional investors and hedge funds.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.